These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 3, 2014. They include Apple, MarkWest Energy Partners, NII Holdings, RF Micro Devices and…
ThinkstockHorizon Pharma Inc. (NASDAQ: HZNP) is having a stellar day after breaking news that it entered into a pact with AstraZeneca PLC (NYSE: AZN) for the U.S. rights to VIMOVO. The move…
Jon C. Ogg ThinkstockMerck & Co. (NYSE: MRK) announced it would rid itself of 8,500 workers, many of whom work in the big pharmaceutical company’s R&D operations. Since the return on research investment at Merck…
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top companies…
ThinkstockWith yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact of higher rates on stocks continues to be top of mind for…
Jon OggInvestors are on the hunt for solid research ideas now that stocks have pulled back a bit. 24/7 Wall St. reviews many analyst research calls from Wall Street and from boutique…
ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers expect to be the result.…
ThinkstockOver the past five weeks, the 10-year Treasury bond yield has increased by over one-half of one percent from 1.66% to 2.17%. The overall equity market has rallied 3.8% during this stretch…
U.S. equity markets opened slightly higher this morning but lost steam in the afternoon to finish with a loss for the first Tuesday in a record streak of Tuesdays. In Europe, Spain…
ThinkstockTotal return is always the name of the game when it comes to investing success. Stocks that pay dividends on a regular basis help smooth out the rough spots when the market…
ThinkstockThe world of pharmaceuticals may have faced a patent cliff in recent years, but brand name drugs are still generating billions upon billions in annual sales in the United States alone. Some…
ThinkstockInvestors love dividends, and this component of investing plays a very important part of the total return through time. Buying stocks that combine solid and growing dividends with a potential for capital…
When the holidays wound down and we started off 2013, all the Wall St. firms started to put out their top stock picks for the year. We covered those various lists so…
ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s Bayer A.G. to extend the use of the two companies’ blood thinning…
ThinkstockS&P 500 dividend growth continues to outpace earnings growth, a trend that likely will continue for a few more years. Low yields on fixed income alternatives and historically low dividend payout ratios…
